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The first experiment was conducted to investigate the modulatory effect of 
ovine growth hormone (oGH), ovine prolactin (oPRL), and recombinant bovine 
insulin-like growth factor-I (rbIGF-I) on resting (primary cell culture in absence of 
mitogens) and recombinant bovine interleukin-2 (rbIL-2)-activated peripheral blood 
mononuclear (PBMN) cells from non-pregnant female sheep. PBMN cells were 
treated with oGH, oPRL, and rbIGF-I at various concentrations. Ovine GH and 
oPRL at 100 ng/mL stimulated PBMN cell proliferation (p < 0.05), as measured by 
their uptake of [314]-thymidine. However, when oGH was combined with rbIL-2 
(500 units/well in tissue culture plate), the proliferative response occurred at the 
higher dose (2 Ag/mL). Ovine PRL did not have a proliferative effect on rbIL-2­
activated PBMN cells (p= 0.07).  Insulin-like growth factor-I had no effect on 
proliferation of resting or rbIL-2-activated (p > 0.05) PBMN cells. 
The second experiment was carried out on lamb PBMN cells to assess the 
development of growth hormone (GH) receptor from birth to 5 months. Growth 
hormone-binding protein (GHBP) was also measured in plasma from the same 
animals in which GH receptors were measured. 
Redacted for PrivacySpecific binding of 125I-hGH to the GH receptor on PBMN cells increased from 
0.3% at d 7 to 0.8 + 0.1% at d 150 (p < 0.03). Plasma GHBP concentrations 
increased (p < 0.001) from d 30 to d 150. 
The third experiment was carried out to develop an assay to measure soluble 
interleukin-2 (sIL-2) receptor in serum from ruminant animals using recombinant 
bovine interleukin-2 (rbIL-2) and to assess sIL-2 receptor activity in serum from 
calves treated with selenium (Se), vitamin E and Se + vitamin E. Serum sIL-2 
receptor activity also was measured in cows with a positive antibody titer against 
bovine viral diarrhea (BVD) and infectious bovine rhinotracheitis (IBR) viral 
diseases.  Selenium, vitamin E, and Se + vitamin E had no effect on serum sIL-2 
receptor binding activity. However, the occurrence of scours (animal diarrhea) was 
associated with an increase (p < 0.01) in serum sIL-2 receptor activity from 1.8 + 
0.1 percent specific activity (%SB) in scours-free to 2.5 + 0.1 %SB for scours 
animals. Serum sIL-2 receptor activity was 5.2 + 0.8 %SB in infected cows with 
BVD virus and IBR, which was higher (p < 0.01) than that in non-infected cows 
(3.0 + 0.2).  Therefore, the serum levels of sIL-2 receptor are elevated in response 
to several specific infectious diseases, including viral and bacterial infections. These 
data suggest that serum sIL-2 receptor may serve as a marker for the immune status 
of an animal to viral and bacterial infections. 
According to these studies, lamb PBMN cells carry GH and PRL receptors. 
Growth hormone and PRL can modulate the proliferation of PBMN cells in vitro. 
Serum sIL-2 receptor might be used to determine the status of the immune system in 
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CHAPTER I
 
INTRODUCTION
 
In order to bring the self-regulated immune system into conformity with 
other body systems its functioning within the context of an immune-neuroendocrine 
network is proposed (Besedovsky and Sorkin, 1977). This hypothesis is based on 
the existence of afferent pathways between immune and neuroendocrine structures. 
A new interdisciplinary research area has recently emerged that involves the study of 
interactions between the immune and endocrine systems. Numerous bidirectional 
interactions between these two systems have been described (Kao et al., 1992). 
The first point that bears emphasizing is the remarkable near-parallel development of 
the immune and endocrine systems in various mammalian species during early 
ontogeny. This can hardly be fortuitous.  Species such as mice and rats have, at 
birth, only marginal levels of immunoglobulins and their immune responses are 
minimally effective during the first days of extrauterine life. Many endocrine 
systems are also underdeveloped at this time (Solomon, 1971), notably sexual 
differentiation, functioning of the hypophysis, thyroid and adrenal glands (Jost et 
al., 1973). 
Among the newly recognized interactions between the immune and endocrine 
systems is the observation of an increasing number of peptides and proteins that are 
used in both systems as intercellular messengers (Blalock, 1992). Adrenocorti­
cotropic hormone (ACTH) was the first hormone that was found to be synthesized in 2 
the immune system by lymphocyte (Smith and Blalock, 1981). A number of other 
hormones, including growth hormone (GH) (Baxter et al., 1991a), prolactin (PRL) 
(Gala and Shevach, 1994) and insulin-like growth factor (IGF-I) (Baxter et al., 
1991b) have also been shown to be synthesized by or associated with cells of the 
immune system.  Since these hormones can also function as immunomodulators, it is 
proposed that cells in the immune system are able to produce GH and PRL-like 
hormones, which can in turn have autocrine or paracrine effects on the immunocytes 
themselves.  Since 1959 GH has been proposed to be an important 
immunoregulatory molecule (Shrewsbury and Reinhardt, 1959). Confirmation of 
this suggestion has occurred through a number of studies both in vitro and in vivo 
(Kelley, 1990). 
The effects of GH on lymphocyte functional responses are mediated through 
specific cell surface receptors which have been identified on both thymocytes and 
lymphocytes (Blalock, 1992). Supposedly, PRL also exerts its immunoregulatory 
effect through a cell surface receptor on immune cells (Vise lli and Mastro, 1993). 
Activation of the immune system, usually initiated by a viral or bacterial 
challenge, brings about a multitude of cellular events leading to the maturation and 
proliferation of lymphocytes (Reinherz and Schlossman, 1980).  Interleukin-2 (IL-2) 
was first described as a factor in supernatants of activated lymphocyte cultures 
capable of stimulating the growth and proliferation of human T-cells in culture 
(Morgan et al., 1976). The receptor for IL-2 has been identified on the surface of 
T-cells and its increased expression has been shown to occur in response to IL-2 3 
release shortly after antigen binding (Smith, 1988). Rubin et al. reported in 1985 
that in addition to de novo expression of IL-2 receptor on the surface of activated 
human peripheral T-cells, a released form of soluble IL-2 receptor (sIL-2) could be 
detected in culture supernatants of activated T-cells. 
Therefore, the objective of these studies was to determine if, in the ruminant 
animal, such interactions also exist.  Specifically the studies were conducted to: 
1.	  Measure specific GH binding on PBMN cells in lambs at different ages. 
2.	  Determine binding affinity (Ka) and binding capacity (B max) of these 
GH binding sites. 
3.	  Characterize specificity of the GH binding. 
4.	  Purify and characterize the GH receptor from PBMN cells membrane. 
5.	  Measure plasma growth hormone binding protein (GHBP) concentrations 
in growing lambs. 
6.	  Examine the responsiveness of PBMN cells to GH, PRL, IGF-I and 
glucocorticoid (GC) with and without IL-2. 
7.	  Develop an assay to measure sIL-2 receptor in serum. 
8.	  Measure specific binding of sIL-2 receptor in plasma in growing lambs. 
9.	  Measure serum sIL-2 receptor activity in calves treated with selenium 
(Se), vitamin E, and Se + vitamin E. 
10. Measure serum sIL-2 receptor activity in diseased and non-diseased 
cows. 4 
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CHAPTER II
 
REVIEW OF LITERATURE
 
Cellular Components of the Immune System 
The immune system, like the endocrine system, is composed of a number of 
specialized cell types that have unique functions and particular sets of chemical 
messengers. The immune system may be regarded as consisting of lymphocytes, 
macrophages, a series of macrophage-related cells including the dendritic cells of the 
spleen and the specialized epithelial cells, such as those found in the thymus (Paul, 
1984). Lymphocytes differ from one another not only in the specificity of their 
receptors but also in their functional properties. Two broad classes (or lineages) of 
lymphocytes are recognized: the T lymphocytes, thymus dependent lymphocytes, 
and B lymphocytes which are precursors of antibody-secreting cells. 
T lymphocytes 
T lymphocytes represent one of two major classes of lymphocytes and derive 
their name from the fact that they and their precursors spend time in the thymus 
(Nikolic-Zugic, 1991). On all T cells are clusters of differentiation (CD) markers 
which are cell surface glycoproteins expressed on subsets of thymocytes and mature 
T lymphocytes (Parnes, 1989). The two main functions of T cells are destruction of 
host cells with altered (or nonself) surfaces and regulation of immune reactions. 7 
The latter function can occur either by direct interaction with other cells or 
indirectly through the production and release of soluble mediators called cytokines. 
B lymphocytes 
The second major class of lymphocytes is termed B-cells, and the name 
refers to the bursa of Fabricius, which is present in birds and is a lymphoepithelial 
organ. The primary site for B cell differentiation in mammals is most probably the 
fetal liver and, following birth, the bone marrow serves in mammals a similar 
function to the Bursa in birds (Kincade, 1981). The primary marker for B 
lymphocytes is the cytoplasmic or cell surface expression of immunoglobulins (Ig). 
Natural killer cells 
A novel cytotoxic activity was described in the lymphoid tissue of rats and 
mice against a wide spectrum of tumor target cells and the activity was present even 
before immunization of the animals, it was called natural killer (NK) cells (Quan, et 
al. 1982).  Natural killer cells are large granular lymphocytes that lack the major 
surface markers that are generally associated with T and B lymphocytes. The 
principal functions of NK cells are the killing of virus-infected and tumor cells in 
the absence of prior sensitization. The predominant lymphokine that is produced by 
these cells is interferon alpha (IFN-a). 8 
Endocrinology of Growth Hormone and Prolactin 
Growth hormone 
The growth-promoting principle of the pituitary gland was isolated in the 
form of GH in 1944 (Li and Evans, 1944). Growth hormone, also known as 
somatotropin, is a 191-amino acid single chain protein with a serum half-life of 20 
to 25 min.  Bovine GH is synthesized as a prehormone with a 26-amino acid 
hydrophobic signal sequence (Lingappa et al.,  1977). Since the signal peptide is 
cotranslationally cleaved, the prehormone is extremely short-lived.  It is secreted by 
the anterior pituitary gland in all mammals and most vertebrates, and the principal 
site of degradation of GH is the kidney, where GH is filtered by the glomerulus and 
subsequently taken up nonspecifically and lysosomally degraded by proximal tubular 
cells (Johnson and Maack, 1977).  Its role in the promotion of growth, coupled with 
changes in the metabolism of proteins, carbohydrates and lipids, is well documented 
(Paladini et al.,  1983). Although GH secretion is maximal at puberty, it declines 
after about 30 years of age in humans (Rudman  et al.,  1990) and low but detectable 
levels are found throughout the remainder of adulthood. This suggests that this GH 
may have other functions in addition to promotion of growth. 9 
Growth hormone receptor 
In the rabbit liver the GH receptor is a 130-kDa protein.  It consists of 620 
amino acids divided into a 246-amino acid extracellular domain, a single 
transmembrane domain of 24 amino acids, and an intracellular domain of about 350 
amino acids (Leung et a/., 1987). The extracellular domain possesses several 
potential sites of N-linked and 0-linked glycosylation, as in most membrane bound 
receptors. The difference between the apparent molecular size (130 kDa) and the 
predicted size by a composition (70 kDa) is thought to be due to a high level of 
glycosylation and covalent association of the receptor with ubiquitin. A 
complementary DNA (cDNA) for the bovine GH receptor has been cloned out of a 
cDNA library prepared from the liver of a Holstein heifer. The cDNA hybridized 
to a single 4.5 kb mRNA species and shares a high degree of sequence homology 
with GH receptors cloned from other species (Hauser et a/., 1990). The 
extracellular portion of the hGH receptor is structurally related to the extracellular 
domain of the prolactin receptor (Boutin et a/., 1988) and broadly related to at least 
eight other members of this receptor superfamily (Cosman et al., 1990; Bazan, 
1990). 
Specific receptor sites have been shown for human GH in a line of cultured 
human lymphocytes (4265) which was initiated in 1965 from peripheral blood cells 
of a patient with chronic myelogenous leukemia (Lesniak et al., 1973). The binding 
of ''I-hGH to these cells was rapid, saturable, and reversible.  Another lymphocyte 10 
cell line (IM-9), initiated in 1967 from bone marrow cells of a patient with chronic 
myelogenous leukemia demonstrated greater binding per cell (4000 binding 
sites/cell) and greater sensitivity to low physiological concentrations (1.3 x 109 M-1) 
of GH (Lesniak et al., 1974). 
Eshet et al. (1975) have reported that the 125I-hGH bound by fresh circulating 
human lymphocytes is displaced only by hGH. Keiss and Butenandt (1985) have 
reported specific binding of 125I-hGH was rapid, reversible and time and 
temperature dependent. Scatchard analysis (Scatchard, 1949) of 125I-hGH binding to 
PBMN revealed a high affinity receptor with a K. of 1.5 x 10-9 M and a maximal 
binding capacity (B max) of 7.1 x 10-11 M. 
Distribution of growth hormone receptor 
Specific GH binding in various tissues have been demonstrated in different 
species (Davis, 1988; Hughes et al., 1985). 11 
Table II. 1. Distribution of GH receptors 
Species	  Tissue 
Liver	  Human (Carr and Friesen, 1976)
 
Mouse (Smith and Talamantes, 1987)
 
Rabbit (Leung et al., 1987)
 
Rat (Baxter, 1985)
 
sheep (Chan et al., 1978)
 
Adipose  Sheep (Chan et al., 1978)
 
Rat (Roupas and Herington, 1986)
 
Thymocytes  Cow (Arrenbrecht, 1974)
 
Mouse (Arrenbrecht, 1974)
 
Lymphocyte  Human (Ashkenazi et al., 1987)
 
Ovary  Sheep (Chan et al., 1978)
 
Muscle  Rat (Satyanarayana et al., 1988)
 
Chondrocyte  Rat (Eden et al., 1983)
 
Growth hormone receptor regulation 
The responsiveness of a target tissue to a hormone is modulated not only by 
the level of circulating hormone but also by the availability of receptors with which 12 
the ligand can interact.  For this reason the regulation of receptor number and 
affinity has been studied extensively in many hormonal systems. The initial studies 
of GH receptor regulation examine the end result of regulation (i.e., changes in 
binding affinity or capacity) rather than the mechanism by which levels of receptors 
are controlled (Hughes et al., 1985).  It is often assumed that an increase in binding 
activity is caused by an increased rate of synthesis of the receptors while a decrease 
in binding represents a "turning off" of the machinery involved in de novo synthesis. 
However, regulation of GH receptors may involve additional factors, including the 
activation/inactivation of pre-existing cryptic receptors that can be switched from a 
nonbinding to a binding state by an appropriate trigger mechanism (Hughes et al., 
1985). Growth hormone receptor exists in a dynamic state of flux and regulation. 
Because GH receptor appears to be essential to the molecular mechanism of GH 
action, modulation of these proteins could significantly alter biological responses to 
GH. Growth hormone receptor appears to be up- or down-regulated by several 
factors.  For example, Kelly et al. (1974) have reported that GH binding sites on 
liver membranes were higher in female rats compared to male controls of all age 
groups ranging from 10 days to adult. While hepatic GH binding in female rats 
increased with age, the GH binding in male animals remained almost constant. 
Posner et al. (1980) have demonstrated that hypophysectomy of lambs resulted in a 
marked reduction, though not a complete disappearance, of their hepatic GH 
receptors. 13 
Growth hormone-binding protein 
The existence of carrier proteins for polypeptide hormones was considered in 
the early 1960s, shortly after radiolabeled hormones became available for 
radioimmunoassay (RIA).  In 1964, Hadden and Prout reported that GH in plasma 
was protein bound. Growth hormone binding protein (GHBP) in human plasma is a 
single-chain glycoprotein with an estimated molecular weight of 50-60 kDa.  It binds 
hGH with high specificity and high affinity (Baumann, 1986, 1990). A serum 
GHBP has been reported from several other species including sheep, pig, and 
chicken (Davis et al., 1992), human (Daughaday et al., 1987), rabbit (Ymer and 
Herington, 1985), mouse (Smith and Talamants, 1988), and rat (Amit et al., 1990). 
It has been shown that the rabbit and human serum GHBP is related to and possibly 
derived from the hepatic GH receptor (Leung et al., 1987; Spencer et al., 1988). 
Characterization of this binding protein shows that it corresponds to the extracellular 
domain of the GH receptor, and it has been proposed that the GHBP may be 
produced by proteolytic cleavage of the membrane-bound GH receptor (Spencer et 
al., 1988), at least in man (Trivedi and Daughaday, 1988).  In both rat and mouse, 
the evidence available suggests that the GH receptor and the GHBP arise 
independently from the same gene by alternative splicing of the precursor mRNA 
(Baumbach et al., 1989).  Specific mRNA transcripts with estimated sizes of 1.2 kb 
and 4.0 kb were found for GHBP and GH receptor respectively in mouse and rat 
(Baumbach et al., 1989).  In the human, GHBP is identical to the extracellular 
domain of the GH receptor but with a hydrophilic tail replacing the hydrophobic 14 
transmembrane domain and the intracellular domain (Baumbach et al., 1989). The 
physiological significance of the GHBP has been reported to be both prolongation of 
the half-life of hGH in the circulation (Baumann et al., 1987) and interference in 
vitro with the binding of 125I-hGH to different GH receptor preparations (Waters et 
al., 1990). 
The expression of GHBP increased with age up to puberty suggesting that it 
is developmentally regulated in a manner similar to GH receptor (Daughaday et al., 
1987). The GHBP mRNA was found in all extrahepatic tissues examined that 
contained GH receptor mRNA. The ratio between the 1.2 kb and 4.0 kb transcripts 
varied between tissues indicating that GH receptor and GHBP transcripts may be 
separately regulated. 
Signalling mechanism of growth hormone 
Although the ability of GH to promote growth and regulate lipid, protein, 
and carbohydrate metabolism has been known for many years (Davidson, 1987), the 
molecular mechanism by which GH binding to its receptor elicits its diverse 
responses has remained an enigma.  It has been shown that GH stimulates the 
expression of c-fos gene (Doglio et al., 1989), an early marker of cell 
differentiation, and the action of protein kinase C might be involved (Smal and 
Meyts, 1987). Accumulation of diacylglycerol (DAG) following GH stimulation has 
been reported in different cell lines (Catalioto et al., 1990). Preliminary data 
suggest that this DAG may be produced from breakdown of phosphatidyl choline or 15 
other cellular glycerophospholipids, by a mechanism (G-protein) coupling a 
phospholipase C to the GH receptor (Rogers and Hammermann, 1989). 
Additional mechanisms of GH action have also been postulated.  For 
example, GH has been reported to promote the phosphorylation of its receptor on 
tyrosyl residues in different cell lines (Stred et al., 1990). Although GH receptor 
lacks homology to receptors with tyrosine kinase activity (Foster et al., 1988), it has 
been shown that GH added to murine 3T3-F442A fibroblasts promoted the in vivo 
phosphorylation of GH receptors on tyrosyl residues (Stred et al., 1993). 
Argetsinger et al. (1993) have recently identified a protein kinase termed JAK2 "Just 
Another Kinase", which is a nonreceptor tyrosine kinase with a molecular weight of 
130 kDa, as a GH receptor-associated tyrosine kinase. Immunological approaches 
(immunoprecipitation) have been used to establish GH-dependent complex formation 
between JAK2 and GH receptor. These data are still fragmentary and do not 
provide a clear understanding of how the hormonal signal is conveyed inside the 
cell. 
Prolactin 
Prolactin is a polypeptide hormone of pituitary origin with close structural 
relationships to GH (Hwang et al., 1972).  Prolactin consists of 199 amino acids in 
a single peptide chain, and has three intramolecular disulfide bonds  . 16 
Prolactin receptor 
The PRL receptor in liver is a single transmembrane polypeptide with 210 
amino acids on the extracellular domain but only 58 amino acids in the cytoplasm 
(Boutin et al., 1988). The sequence of the mature PRL receptor, deduced from the 
cDNA, contains 291 amino acids, with an extracellular region of 210 amino acids, 
single transmembrane region of 24 amino acids, and a relatively short cytoplasmic 
domain of 57 amino acids (Boutin et al., 1988). 
Complementary DNA clones encoding both long and short forms of the 
prolactin receptor have been described (Boutin et al., 1988).  In all the species 
studied to date, the prolactin receptor is closely related to the GH receptor, with 25­
35 % overall homology in their predicted amino acid sequences, especially in the 
extracellular, hormone-binding domain (Boutin et al., 1988). Comparison of the 
cDNA sequences of the GH receptors and of the related PRL receptor suggests that 
they are members of a new family of transmembrane receptors that include the 
receptors for erythropoietin, IL-2, IL-6 and granulocyte- macrophage colony-
stimulating factor (Cosman et al., 1990). The major region of homology between 
all of these receptors resides in the extracellular domain, whereas the 
intracytoplasmic domain shows a high degree of heterogeneity, suggesting different 
signal transduction pathways. 17 
Distribution of prolactin receptor 
Specific PRL binding sites in various tissues have been demonstrated in 
different species and are widely distributed in mammalian tissue (Hughes et al., 
1985). 
Table II. 2. Distribution of PRL receptors 
Species	  Tissue 
Mammary gland	  Mouse (Frantz and Turkington, 1972) 
Rat (Cost low et al., 1974) 
Rabbit (Shiu et al., 1973) 
Liver	  Mouse (Frantz et al., 1974) 
Rat (Herington and Veith, 1977) 
Pituitary cells Rat (Frantz et al., 1975) 
Ovary	  Rat, Cow, (Saito and Saxena, 1975)
 
Human (Saito and Saxena, 1975)
 
Sheep (Posner et al., 1974)
 
Splenocytes  Rat (Vise lli and Mastro, 1993)
 
Nb2  Rat cell line (Shiu et al., 1983)
 
Natural killer cells  Human (Matera et al., 1988)
 
Lymphocytes  Human (Russell et al., 1985)
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Prolactin receptor and immune cells 
Early reports using ligand-binding methods have indicated that the PRL 
receptor is present on peripheral blood lymphocytes and spleen and thymus cells 
(Russell et al., 1984; Bellussi et al., 1987) as well as on large granular lymphocytes 
(Matera et al., 1988).  Recently, using reverse transcription coupled to the 
polymerase chain reaction, PRL receptor gene expression has been reported for 
human T-cells, B-cells, and monocytes (Pellegrini et al., 1992) and for normal 
mouse thymocytes and splenocytes (O'Neal et al., 1991). 
Hormone and the Immune System 
Growth hormone 
Evidence has accumulated indicating that GH not only regulates growth of 
body tissues but can also control important immune functions. Growth hormone 
modulates components of the immune system both in vivo and in vitro.  Studies have 
shown that hypophysectomized rats were unable to exhibit an immune response 
(Berczi and Nagy, 1981). Treatment of hypophysectomized rats with GH or PRL 
actually restored immunocompetence, whereas other pituitary hormones had no 
effect (Berczi and Nagy, 1983). In vitro studies have shown that GH increases the 
proliferation rate of normal lymphoid cells (Davila et al., 1987). These 
observations are consistent with reports that lymphocytes express specific receptors 19 
for GH (Lesniak et al.,  1974; Kiess and Butenandt, 1985). Growth hormone is also 
responsible for modulating other immunologic activities such as augmenting cytolytic 
activity of T cells, antibody synthesis, GM-CSF-dependent granulocyte 
differentiation, TNF-a production, superoxide anion generation from peritoneal 
macrophages of hypophysectomized mice and NK activity (Kelley, 1990). 
Weigent  et al. (1988) and Hattori  et a/. (1990) have reported that 
nonstimulated rat lymphocytes produce immunoreactive GH (irGH) which is 
biologically active and similar in structure to pituitary-derived GH. Lymphocyte-
derived irGH is secreted spontaneously in culture while pituitary GH is secreted 
under the control of growth hormone releasing hormone (GHRH). Additionally, 
lymphocyte-derived irGH can compete with iodinated pituitary GH for binding to rat 
lymphocyte GH receptors (Carr  et a/., 1989). Rat Nb2 lymphoma cells, which are 
dependent on lactogens for growth, have been used extensively to assay human 
serum lactogen concentrations (Tanaka et al., 1980) and to study the mechanism of 
action of these hormones as mitogens. 
The role of GH in lymphocyte proliferation has been studied by examining 
the effect of an antisense oligodeoxynucleotide complementary to GH mRNA in the 
rat (Weigent et al.,  1991).  Antisense GH oligodeoxynucleotide treatment inhibits 
production of irGH by lymphocytes. Antisense GH oligodeoxynucleotide-mediated 
inhibition of irGH production resulted in a decrease in lymphocyte proliferation. 
Collectively, these data indicate that lymphocytes synthesize and secrete irGH and 20 
that irGH produced by these cells can stimulate proliferation, suggesting that GH 
may play an autocrine/paracrine role in lymphocyte replication. 
Prolactin 
Numerous studies have indicated that PRL is involved in immune functions 
(see review by Gala, 1991). Hypophysectomized rats have impairments in both 
humoral and cellular immunity (Nagy and Berczi, 1978), and PRL administration 
restored these functions (Berczi and Nagy, 1991).  Further, the administration of 
bromocriptine, which specifically blocks PRL secretion, resulted in suppressed 
immune function similar to that caused by hypophysectomy, and PRL administration 
corrected the function (Berczi et al., 1981). 
Mukherjee et al. (1990) have reported that PRL induced the IL-2 receptor on 
the rat splenic lymphocyte. A more consistent finding in vitro has been the blocking 
of lymphocyte proliferation in response to a number of stimulants and cytokines by 
anti-PRL antisera (Hartmann et al., 1989: Clevenger et al., 1990).  Interleukin-2 
stimulation induced the translocation of PRL into the nucleus and PRL receptor to 
the nuclear periphery.  Clevenger et al. (1991) suggested that extracellular PRL is 
requisite for T cell proliferation and that the effects of PRL are exerted in the 
nucleus. A number of investigators have reported the presence of a PRL-like 
message and the secretion of PRL-like activity from murine splenocytes involved 
with immunity (Montgomery et al., 1987).  Increased expression of growth-related 
genes, such as ornithine decarboxylase and c-myc, has been shown to occur in cells 21 
treated with PRL (Berczi and Nagy, 1991).  Prolactin has been shown to be secreted 
from a human B lymphoblastoid cell line variant designated as IM-9-p3 (DiMattia et 
al., 1988). PRL synthesized by these cells was indistinguishable from human 
pituitary PRL, however the mRNA species expressed by these cells differed from 
that of pituitary origin in that it was approximately 150 bases longer than expected. 
Further confirmation of the identity of this PRL is demonstrated by the fact that the 
immunoaffinity-purified lymphocyte PRL is of the same molecular weight as human 
pituitary PRL (DiMattia et al., 1988). A 46-kDa PRL-like molecule has been 
shown to be secreted by mitogen-driven rodent lymphocytes as compared to the 25­
kDa pituitary PRL (Montgomery et al., 1987). These findings would suggest that 
PRL and/or PRL-like molecules play an important role in positive regulation of 
lymphocyte functions. 
The pre-T cell rat Nb2 lymphoma cell line is almost completely dependent 
on lactogenic hormones for growth and contains receptors with high affinity for PRL 
(Shiu et al., 1983). This cell line constitutes a useful system to measure the 
biological activity of PRL (at the picogram per mL level) and to analyze one of the 
mechanisms of PRL action, i.e. cell multiplication. 
Insulin-like growth factor-I 
The insulin-like growth factors comprise a family of peptides which promote 
proliferation and differentiation of various cell types (Froesh et al., 1985).  Insulin-
like growth factor-I, a 70-amino acid peptide structurally related to insulin, is 22 
normally considered to be a metabolic hormone which mediates many of the 
anabolic effects of GH. Insulin-like growth factor-I is predominantly synthesized in 
the liver, but it can also be produced by a variety of tissues where it can act as an 
autocrine or paracrine growth factor (D'Ercole et al., 1984).  Insulin-like growth 
factor-I is a single chain polypeptide containing three disulfide bonds with 7.5 kDa 
and with blood plasma concentration of 200 ng/mL in man (review, Humbel, 1990). 
Insulin-like growth factor-I is a mitogenic polypeptide that has been 
implicated in the regulation of fetal growth (D'Ercole, 1987). The mitogenic effect 
is mediated by a specific IGF-I receptor which is a receptor kinase and which is 
homologous to the insulin receptor.  In vitro effects of IGF-I are commonly 
classified into short-term insulin-like metabolic effects such as stimulation of glucose 
uptake and glycogen and lipid synthesis in adipose tissue, and long-term mitogenic 
effects such as stimulation of protein, RNA, and DNA synthesis and cell 
proliferation (Humbel, 1990). 
A role for IGF-I in the immune system is suggested by the expression of 
IGF-I in human macrophages and a lymphoblastoid cell line (Merimee et al., 1989). 
Furthermore IGF-I might be involved in lymphocyte proliferation as suggested by 
the effects of both growth factors on the in vitro proliferation of lectin-activated 
lymphocytes (Tapson et al., 1988), and by the increased expression of its receptors 
on activated T cells. 23 
Glucocorticoid 
Steroid hormones are important modulators of eukaryotic gene expression. 
Generally, these hormones enhance gene expression by stimulating the synthesis of 
specific mRNA. For example, glucocorticoids (GC) such as dexamethasone 
stimulate the transcription of growth hormone (Spindler, 1982).  Clinically, 
glucocorticoids are used as immunosuppressive and anti-inflammatory agents. Their 
immunosuppressive effects may in part be due to their catabolic functions (Arya, 
1984).  Glucocorticoids may inhibit the transcription of genes responsible for the 
immune functions of lymphocytes and may interfere with the synthesis or functions 
of IL-2, eventually resulting in a suppressed immune response (Gillis  et al.,  1979). 
Glucocorticoids suppress the proliferation of human T lymphocytes.  Gillis et al. 
(1979) have demonstrated that dexamethasone, a synthetic GC, inhibits the 
production of IL-2 by mitogen-activated lymphocytes. 
Interleukin-2 
Interleukin-2 is a glycoprotein with an apparent molecular mass of 15.5 kDa 
(Bazan, 1990).  Interleukin-2, also known as T cell growth factor (TCGF), is an 
immunomodulatory factor produced by T- lymphocytes and has been isolated from a 
variety of cell cultures and recombinant systems (Smith, 1988).  Interleukin-2 has 
been shown to promote long term growth of activated T cells (Morgan et al.,  1976), 24 
activation and proliferation of natural killer (NK) cells, and induction of gamma 
interferon (gamma INF) and B cell growth factor secretion (Ortaldo et al., 1984). 
Interleukin-2 receptor 
The receptor for IL-2 plays a crucial role in the regulation of the immune 
response (Smith, 1988). Binding of IL-2 to its receptor on the surface of T 
lymphocytes triggers a series of intracellular signaling events that result in the 
activation and proliferation of resting T cells and, ultimately, in the generation of 
helper, suppressor and cytotoxic T cells, which mediate immune reactions 
(Waldman, 1986). 
There are three forms of the cell-membrane IL-2 receptor, each with a 
different affinity for IL-2 (Wang et al., 1987; Sharon et al., 1988). The low 
affinity receptor (dissociation constant, Kd, approximately 10 nM) is a 55-kDa 
polypeptide (p55), the intermediate affinity receptor (Kd  1 nM) is a 75-kDa 
polypeptide (p75), and the high affinity receptor (Kd  10 pM) is a noncovalent 
complex containing p55 and p75 (Robb et al., 1984) on both T and B cells 
(Lowenthal et al., 1987).  It has been generally believed that the high-affinity 
receptor is responsible for transducing the IL-2 signal for cellular proliferation 
(Smith and Cantrell, 1985).  In the presence of an antigen, T cells are induced to 
synthesize and secrete IL-2 as well as to synthesize cell-surface IL-2 receptor. 
Different affinity forms of IL-2 receptor are synthesized upon stimulation, leading to 
increased numbers of high affinity receptors on the cell surface.  It appears that 25 
binding of IL-2 to high affinity receptors is the trigger necessary to promote cell 
cycle progression (Smith and Cantrell, 1985). The p55 molecule of the IL-2 
receptor does not seem capable of generating such a second signal. The newly 
described p75 molecule is an attractive candidate for being the signal-generating 
protein of this receptor complex. 
Interleukin-2 receptors are members of the hematopoietic receptor 
superfamily, which also includes receptors for IL-3, IL-4, IL-6, IL-7, granulocyte 
macrophage colony stimulating factors (GM-CSF), PRL, GH and erythropoietin 
(Bazan, 1990). Weinberg et al. (1988) have demonstrated that the bovine and 
human IL-2 receptor coding sequences revealed 71% homology at the nucleotide 
level. 
Serum-soluble form of IL-2 receptor 
The generation of anti-IL-2 receptor monoclonal antibodies that recognize 
different epitopes of IL-2 receptor led to the detection of a truncated form of the 
receptor, which has an apparent molecular mass of approximately 45 kDa, and 
which is secreted by activated T cells (Rubin et al., 1986 ).  The secreted form of 
the IL-2 receptor has been identified as the IL-2 receptor lacking the transmembrane 
and intracytoplasmic tail (Shimizu et al., 1986). This serum soluble form of IL-2 
(sIL-2) receptor binds IL-2 with low affinity (Rubin et al., 1986). The way the high 
affinity receptor may function is that the p55 molecule rapidly associates with IL-2, 
bringing it into close proximity to the p75 molecule which might undergo a 26 
conformational change causing IL-2 to associate with faster kinetics (Tsudo et al., 
1987). The presence of low levels of sIL-2 receptor has been reported in the serum 
of mice (Osawa et al., 1986), rats (Mouzaki et al., 1987) and humans (Rubin et al., 
1986). The major difference between the soluble and cell-surface forms of low 
affinity IL-2 receptor is that the former comprises only the ligand-binding domain 
and lacks both transmembrane and cytoplasmic domains (Robb and Kutny, 1987). 
Serum soluble IL-2 receptor and p55 contain similar N- and 0-linked sugar 
modifications and both bind IL-2 with the same low affinity (Jacques et al., 1987). 
The sIL-2 receptor appears to be generated by proteolytic degradation of cell-surface 
p55, rather than by the posttranscriptional splicing mechanism (Robb and Greene, 
1987). Considerable interest has developed in the use of serum sIL-2 receptor as a 
prognostic or diagnostic indicator of the immune status in an individual. The level 
of sIL-2 receptor in serum is considered as an estimator of T cell activation and has 
been reported to increase in a wide spectrum of diseases (Rubin et al., 1990). 
Nutritional Effects on the Immune System 
The immune system, like all systems in the body, is dependent on the 
availability and utilization of nutrients for optimal maintenance and function of its 
components (Chandra, 1985). 27 
The role of vitamin E in immune function 
Vitamin E (dl-ce-tocopherol) acts as an important antioxidant in cellular 
membranes; its main function is to protect the unsaturated bonds of cellular 
membrane phospholipids against free radical attack (Tappel, 1972). 
Tengerdy et al. (1984) have reported that dietary supplementation with 
vitamin E leads to enhanced humoral immune responses and increases resistance to 
bacterial infection in mice and chickens. Tanaka et al. (1979) have found that 
dietary supplementation of vitamin E induces the enhancement of helper T cell 
activity in mice. Afzal et al. (1984) found in rams that dl-a-tocopherol acetate used 
as an adjuvant to Bruce lla ovis vaccine decreased overall infectivity against an 
experimentally induced infection, compared to a Bruce lla ovis-Freund's incomplete 
adjuvant preparation. This protective effect of vitamin E was not directly related to 
an increase in antibody titer but rather appeared to be mediated by effects on cellular 
and local immunity.  It is of interest that injection of vitamin E without the vaccine 
also decreased infectivity, albeit less than the Bruce lla ovis-vitamin E adjuvant; a 
vitamin E injection was more effective than an oral supplement (Tengerdy et al., 
1983). 
Vitamin E enhances antibody biosynthesis and cell mediated immunity in 
vivo (Meydani et al., 1990). Gogu and Blumber (1993) have reported that vitamin 
E increases cellular growth and glycosylation in the murine cytotoxic T-cell line 
(CTLL), perhaps via increasing the expression of the IL-2 receptor.  Vitamin E has 
been demonstrated to affect the immune response by enhancing antibody biosynthesis 28 
and cell mediated immunity in vivo (Gogu, 1993). The effect of vitamin E on T cell 
differentiation in the thymus of F344 rats has been examined (Moriguchi et al., 
1993). The ratio of CD4+ CD8- /CD4- CD8- T cells increased in the high vitamin E 
group and significantly decreased in the vitamin E-free group compared to that of 
the regular group. Production of IL-2 by thymocytes following stimulation with 
concanavalin A (ConA) for 48 h increased about threefold in the vitamin E group 
compared to the regular group (Moriguchi et al., 1993). Conversely, thymocytes 
from rats fed the vitamin E-free diet showed a significant decrease in IL-2 
production compared to the regular group. 
Selenium 
A number of minerals appear to influence the immune response.  It is, 
however, difficult to dissociate the effect of one mineral from the other. Roy et al. 
(1993) have shown that dietary (1x10-' M) supplementation with selenium (Se,) 
results in a significant upregulation of the expression of both p55 and p75 subunits 
of the IL-2 receptor on the surface of ConA-stimulated lymphocytes from mice. 
Selenium deficiency is associated with a depression of humoral-immune 
responsiveness, with lower eventual titer of antibody. Mice fed selenium-deficient 
diets during gestation and lactation had reduced growth and lower IgM and IgG 
responses to antigens in plaque assays than did mice fed the same diets only after 
weaning (Mulhern et al., 1985). The deficiency of Se is corrected with vitamin E, 29 
suggesting close interactions between these two nutrients.  T-cell activation is 
dependent on adequate amount of Se (Fischbach et al., 1984). 
Viral Diseases 
Bovine viral diarrhea virus 
Bovine viral diarrhea (BVD) virus has been associated with diarrhea and 
enteric problems (Radostits and Littlejohns, 1988), abortion (Kahrs, 1968), and 
immunosuppression (Markham and Ramnaraine, 1985).  Signs of acute disease 
include diarrhea, ulceration of the mucosal surface of the mouth, esophagus, 
stomach and intestines, fever, depression, and leukopenia (Kahrs, 1971). When 
pregnant cows become infected with BVD virus up to day 125 of gestation, the calf 
may be aborted or become chronically infected (Radostits and Littlejohns, 1988). 
Occasionally researchers have reported isolation of BVD virus from lungs of 
cattle with respiratory disease.  Reggiardo (1979) stated that BVD virus was isolated 
from 21 % of bovine lungs with pneumonia in cases of shipping fever. 
Infectious bovine rhinotracheitis 
The respiratory form of infectious bovine rhinotracheitis (IBR) is 
demonstrated by fever, anorexia, rapid breathing and clear to mucopurulent 
discharge (Rahrs, 1977). An alpha herpesvirus of the family Herpesviridae was 30 
isolated which is now called bovine herpesvirus type 1 (BHV-1) or IBR.  Incubation 
is 2-6 days, morbidity ranges from 10-100%, but mortality is low (0-10%).  In field 
conditions, about 25% of BHV-1-infected cows abort 8 to 100 days (Rahers, 1977). 31 
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Abstract 
This study examined the effect of growth hormone (GH), prolactin (PRL), 
insulin-like growth factor-I (IGF-I), and glucocorticoid (GC) on modulating the 
proliferative responsiveness of peripheral blood mononuclear (PBMN) cells in either 
the presence or the absence of recombinant bovine interleukin-2 (rbIL-2) stimulation. 
Blood samples were drawn from crossbred 2-year old sheep.  Peripheral blood 
mononuclear cells were separated by Ficoll gradient centrifugation. The 
proliferation of PBMN cells were measured by counting the [3H]- thymidine 
incorporation into PBMN cells cultured in vitro.  Tritiated thymidine uptake by cells 
was both time and dose-dependent as it was measured by mitogen stimulation with 
concanavalin A (ConA), phytohemagglutinin-M (PHA), and rbIL-2. Ovine growth 
hormone (oGH) and ovine prolactin (oPRL) at 100 ng/mL had a stimulatory effect 
(p < 0.05) on PBMN cell proliferation in an in vitro assay.  However, when oGH 
was combined with rbIL-2 (500 units/well), the proliferative response occurred at 
the higher dose of 1 or 2 Ag/mL. Ovine PRL did no have a proliferative effect on 
rbIL-2-activated PBMN cells (p= 0.07). Treatment with rbIGF-I had no effect on 
PBMN cell proliferation, either of resting or rbIL-2-activated PBMN cells (p > 0.3 
and 0.7 respectively).  Dexamethasone (a synthetic glucocorticoid) had a suppressive 
effect with rbIL-2-activated cells at a dose as low as 63 ng/mL. These data indicate 
that functionally significant receptors for GH, PRL, and GC are present on PBMN 
cells in sheep. 44 
Furthermore, the results suggest that cells which were stimulated by rbIL-2 had 
reduced numbers of activity of GH or PRL binding sites. 
Key words: Growth hormone, prolactin, interleukin-2, and PBMN cells 45 
Introduction 
Numerous interactions between the endocrine and immune systems have been 
described in recent years.  Both systems share a set of hormones and their respective 
target cell receptors, which can be used for intra and intersystem communication 
(Blalock, 1989). Growth hormone and PRL reportedly modulate immune function 
both in vivo and in vitro. The injection of GH into hypophysectomized animals 
enhanced the antibody response to antigen and accelerated skin graft rejection (Nagy 
et al., 1983). In vitro studies have shown that GH increases the proliferation rate of 
normal lymphoid cells in rodents (Davila et al., 1987). Weigent et al. (1988) have 
reported that nonstimulated rat lymphocytes produce immunoreactive GH (irGH) 
which is biologically active and similar in structure to pituitary-derived GH. 
Growth hormone produced by lymphocytes is similar to pituitary GH in terms of 
bioactivity, antigenicity, and molecular weight (Hattori et al., 1990). Weigent et al. 
(1991) have reported that an antisense GH oligodeoxynucleotide treatment inhibits 
production of irGH by lymphocytes in rat.  Antisense GH oligodeoxynucleotide­
mediated inhibition of irGH production and it resulted in a decrease in lymphocyte 
proliferation. 
Prolactin is involved with a variety of physiological effects on growth and 
reproduction in male and female vertebrates of several species (Nicoll, 1974) and 
also plays a role in the regulation of the humoral and cellular immune system 
(Berczi and Nagy, 1986).  Prolactin can induce interleukin-2 (IL-2) receptor 46 
expression in splenocytes from ovariectomized (OVX) female rats (Vise lli et al., 
1991).  Prolactin potentiates proliferative responses of T-cells to suboptimal doses of 
the T-cell mitogen ConA (Spangelo et al., 1985).  Prolactin receptors have been 
detected on human B- and T-lymphocytes (Russell et al., 1985) and on cells from 
sheep lymphoid tissues. 
A role for IGF-I in the immune system is suggested by the expression of 
IGF-I receptors in human macrophages and a lymphoblastoid cell line (Merimee et 
al., 1989). Furthermore IGF-I might be involved in lymphocyte proliferation as 
suggested by its effect on the in vitro proliferation of lectin-activated lymphocytes 
(Tapson et al., 1988) and also by its inhibitory effect on lymphocyte proliferation as 
reported by Hunt and Eardley, 1986. 
Corticosteroids are thought to be "lympholytic" in vivo because their 
administration is followed by lymphopenia and decrease in size of lymphoid organs, 
particularly lymph nodes and thymus (Claman et al., 1971).  Corticosteroids are 
also immunosuppressive, and this property is felt to be correlated with their 
lympholytic activity. The immunosuppressive effects of GCs are thought to be 
mediated by intracellular GC receptors (Wiegers, 1993). 
The objective of this experiment was to: 
1.	  Assess the mitogenic effect of ConA, PHA, and IL-2 on sheep PBMN 
cells in vitro. 
2.	  Determine the effects of oGH, oPRL, and IGF-I, on resting primary 
PBMN cells in culture. 47 
3.  Determine the effects of oGH, oPRL, IGF-I, and GC on sheep PBMN 
cells activated in vitro by IL-2. 48 
Materials and Methods 
Chemicals 
Ovine prolactin (oPRL), ovine growth hormone (oGH), and human growth 
hormone (hGH) were gifts from the National Hormone and Pituitary Program'. 
Fetal bovine serum (FBS) and RPMI medium 1640 were obtained from Gibco 
Laboratories'. Tritiated thymidine (3H-thymidine) was purchased from Amersham3. 
Ficoll-Histopaque, with a density of 1.077 iug/mL, and dexamethasone, were 
obtained from Sigma'. Recombinant bovine IGF-I (rbIGF-I) was obtained from the 
Monsanto Company'. 
Isolation of PBMN cells 
Heparinized blood samples were drawn from 2 year old sheep via jugular 
venipuncture in vacutainer tubes and then the tubes were placed on ice while being 
1 National Hormone and Pituitary Program, NIDDK, USDA, Rockville, MD 20850.
 
OGH, NIDDK-oGH-15, oPRL, NIDDK-oPRL-20, and human GH,
 
NIDDK-hGH-I-3.
 
2 Gibco, Grand Island, New York.
 
3 Amersham, PRN .1004, Arlington Heights, IL.
 
4 Sigma Chemical, St. Louis, MO 63178
 
5 Monsanto Company, St. Louis, MO 63038
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transported to the laboratory. The PBMN cells from whole blood were isolated 
using a density gradient centrifugation method (Boyum, 1968) using Ficoll 
Histopaque at 1000 x g for 30 minutes at room temperature (RT) and then 
resuspended in complete RPMI 1640 with L-glutamine containing 25 mM HEPES 
buffer, 25 mM sodium bicarbonate, and gentamicin4 (50 ',tenth).  Cultures initiated 
on the same day as that blood samples were collected.  Freshly isolated sheep 
PBMN cells from six animals were examined for their capacity to respond to oGH, 
oPRL, rbIGF-I, and dexamethasone. The PBMN cells were counted using a 
hemocytometer chamber. Cell viability was determined by exclusion of 1% trypan 
blue, and it exceeded 95 % in all preparations. 
Proliferation assay 
To assess immune function, mitogen-induced proliferation of the lymphocytes 
was determined. The PBMN cells (0.5 x106) were cultured in triplicate in 200 /AL 
volumes in culture medium containing RPMI 1640 supplemented with 5% heat 
inactivated (45 min at 56° C) fetal bovine serum (FBS) in 96-well tissue culture 
plates'.  Various concentrations of different mitogens were incubated with isolated 
PBMN cells. Then the tissue culture plates were incubated in a 37° C, 5.0% CO2 
environment for 72 h. To measure DNA synthesis as an indicator of cell 
replication, 1 pCi [3H]- thymidine was added to each well after 72 h, and 
6 Becton Dickinson 50 
incubated overnight (16 h), and then cells were harvested onto 102 x 256 mm glass 
fiber' filters with a 12 multiwell cell harvester' and the filter papers were air dried. 
Incorporated radioactivity was measured using a liquid scintillation cocktail 
(Cytoscint8) and counted in a Beckman gamma counter9 and triplicate determinations 
were averaged. 
Experiments: 
Effects of mitogens on the PBMN cells 
Various concentrations of several mitogens were incubated with isolated 
PBMN cells to determine the optimal concentrations of mitogens for optimum 
responses and also to determine the incubation period. Ten Al of mitogen (either 
PHA' or ConA1°) at concentrations starting at 0.125, 0.25, 0.50, 1.0, and 
increasing to 2 pg/mL, and recombinant bovine IL-211 at concentrations from 10, 
100, 500, 1000, and 2000 units/mL, were added to each well. One unit of rbIL-2 
contained 0.01 ng/mL of IL-2.  Controls contained PBMN cells and media only. 
7 Skatron Inc. Sterling, VA 
8 ICN Biomedicals Ins. Irvine, CA 92713 
9 Beckman Instruments Inc., Fullerton, CA 
1° Calbiochem corporation, La Jolla, CA 
11 Dr. C.  Morrison, Ciba Geigy. Saint. Aubin, Switzerland. 51 
Effects of oGH and oPRL on the PBMN cells 
In this experiment, resting or rbIL-2 activated cells from 8 sheep were treat 
ed with oGH and oPRL at concentrations of 0.01, 0.1, 0.5, 1 and 2 pg/mL. 
Activated PBMN cells were treated with 500 units of rbIL-2 per well. 
The tissue culture plates were incubated in a 37° C, and 5.0% CO2 environment for 
72 h.  Controls for resting PBMN cells contained cells and media only; controls for 
activated cells contained rbIL-2 (500 units/well), cells and media. This experiment 
was repeated with PBMN cells of 8 sheep.  Proliferation responses are expressed as 
[3H1- thymidine uptake at percent of control. 
Effects of IGF-I and dexamethasone on the PBMN cells 
In this experiment, resting or rbIL-2-activated PBMN cells were treated with 
rbIGF-I at concentrations of 0.001, 0.01, 1.0, 100, 500, and 1000 ng/mL. 
Dexamethasone at concentrations at 63.0, 125, 250, 500, and 1000 ng/mL was 
added to the activated cells.  Activated PBMN cells were treated with 500 units/well 
in the tissue culture plate.  Controls for resting cells contained cells and media only; 
controls for activated cells contained rbIL-2 (500 units/well), cells and media. The 
plates were incubated in a 37° C and 5.0% CO2 for 72 h. 52 
Statistical analysis 
Because absolute proliferation levels of PBMN cells displayed large 
heterogeneity between animals, results are expressed as a percentage of control 
(mean ± SE).  Effects of oGH, oPRL, and rbIGF-I on resting and rbIL-2-activated 
PBMN cells were investigated using a factorial treatment structure in a randomized 
complete block experimental design. The statistical model used for analysis included 
the main effects of resting or activated cells, hormone treatment at different 
concentrations (0, 10, 100, 500, 1000, or 2000 ng/mL), and the interactive effects 
of cells x hormone treatment. The blocks correspond to individual animals. That 
is, PBMN cells from the same sheep were randomly assigned to all treatment 
combinations formed from the two factors. The general linear models (GLM) 
procedure in SAS, 1985, was used for the analysis of variance and comparison of 
treatment means. Since proliferation values were not normally distributed among 
the subjects, the natural logarithm was used for statistical analysis. 53 
Results and Discussion 
Effects of mitogens on sheep PBMN cells 
Proliferative responses for nonstimulated and mitogen-stimulated PBMN cells 
are presented in Table 1.  Intraassay coefficients of variance, based on triplicate 
measurements on the same samples, were 8 to 10%. Both ConA and PHA 
significantly increased proliferation (p < 0.0001). The effect of ConA (Fig. 1) was 
present at a dose of 0.125 gg/mL while the PHA effect was observed at doses of 
0.25 itg/mL and above. peripheral blood mononuclear cells proliferated in vitro in 
response to concentrations of rbIL-2 by as low as 100 units per mL at (p < 
0.0001), as shown in Fig. 2. 
Proliferation of PBMN cells in response to oGH and oPRL 
Whether GH and/or PRL regulation of PBMN cells proliferation is 
facilitative or inhibitory appears to depend upon hormonal concentration. There 
were a statistically significant interaction between resting or activated cells and 
treatment effect of oGH (p < 0.01) or oPRL (p < 0.01) on cell proliferation. The 
effect of the oGH or oPRL was analyzed separately for resting and activated PBMN 
cells.  Growth hormone had a significant dose-related effect on cell proliferation, no 
matter whether PBMN cells were activated with rbIL-2 or not (Figs. 3 and 5). 
Ovine GH had a proliferative effect on resting cells at 100 ng/mL (p < 0.01) and 
on rbIL-2-activated cells (p < 0.002) at 2 gg/mL. 54 
These results with sheep PBMN cells are in agreement with those of Mercola 
et al. (1981) who showed that hGH had proliferative activity at 100 ng/mL on 
healthy human PBMN cells.  Ovine PRL had a proliferative effect on resting cells at 
100 ng/mL (p < 0.01) (Fig. 5).  However, when oPRL was used in combination 
with rbIL-2-activated cells, the proliferative effect of PRL on PBMN cells was not 
significant (p= 0.07) (Fig. 6).  Schimpff and Repel lin (1989) have shown that hGH 
had no proliferation effect on PHA-activated human lymphocytes which is in 
agreement with our results from rbIL-2-activated cells.  Resting PBMN cells treated 
with GH and/or PRL shows two different response curves (Figs. 3 and 4), one from 
0 to 0.1 µg /mL and another from 0.5 to 2µg /mL. This result may suggest that 
there are two populations of receptors, one with high affinity and one with low 
affinity. The low affinity response is still present in IL-2 activated cells (Fig. 5 and 
6), suggesting that a disappearance of the high affinity receptors.  Elvinger  et al. 
(1991) have reported that bovine somatotropin (BST) treated cows had not 
proliferative response up to 1000 ng/mL on the resting or mitogen activated (ConA, 
PHA) lymphocytes.  In contrast, Burton (1990) indicated that lymphocytes isolated 
from BST-treated cows had enhanced responsiveness to stimulation with ConA. 
Clevenger et al.  (1990) reported that PRL is needed for cell proliferation of the 
murine T-helper lymphocyte L2 cell line (an IL-2-driven T-cell) because anti-PRL 
antibody in the cell culture medium prevented cell proliferation in comparison to a 
control culture which contained 10 Ag of exogenous PRL per mL of medium and 
exhibited normal cell proliferation. The results show that the response of PBMN 55 
cells to rbIL-2 is influenced by the presence of oGH and/or oPRL at low doses. 
Croze et al. (1988) have reported that after five passages of Nb2 (a lymphoma cell 
line) cells in serum-free medium supplemented with hGH, the maximal proliferation 
of cells in response to IL-2 gradually declined to that of the control cells which just 
treated with IL-2. 
Effects of other hormones on proliferation of sheep PBMN cells 
Treatment of resting PBMN cells with rbIGF-I is shown in Fig. 7.  Insulin-
like growth factor-I did not modulate cell proliferation (p <0.3) in tissue culture. 
In bone marrow transplant studies, rhIGF-I increased the rate of T and B cell 
repopulation of the periphery after lethal irradiation, suggesting that rhIGF-I acts at 
the level of the bone marrow rather than inducing proliferation of peripheral 
lymphocytes (Clark et al., 1993).  Indeed, a recent article by Landreth et al. (1992) 
indicates that IGF-I is produced locally by bone marrow stromal cells and may play 
a role in regulating primary B cell lymphopoiesis. Tapson et al. (1988) have 
reported that IGF-I stimulated uptake of [3H]- thymidine into resting human T 
lymphocytes to a significantly greater extent than occurred in control cells, or cells 
incubated with IL-2 alone. The effect of IGF-I on rbIL-2-activated PBMN cells is 
shown in fig. 8.  Insulin-like growth factor-I did not have proliferative effect on 
rbIL-2-activated PBMN cells (p > 0.7).  It seems in figure 8 that rbIGF-I had an 
inhibitory effect on cells activated by rbIL-2 at the dose of 1 pg/mL. In various 
biological systems, IGF-binding proteins (IGFBPs) have been shown to inhibit IGF-I 56 
function (review by Hintz, 1990).  In tissue culture, IGFBPs can be produced by 
monocytes (Kooijman, 1992).  In our study, our PBMN cell preparation contained 
about 4 to 6% monocytes.  If these cells produced enough IGFBP, this could 
interfere with the effect of IGF-I on cell proliferation in our studies.  Another 
possibility is that the fetal calf serum contained high concentrations of endogenous 
IGF. Therefore, additional IGF-I would produce no additional effects.  Hunt and 
Eardley (1986) have also reported that IGF-I at a concentration of 1 itg/mL had a 
suppressive effect on IL-2-activated splenocytes in tissue culture. Although the 
biologic significance of these observations still needs clarification, the possibility that 
IGF-I links the endocrine and immune systems deserves further consideration.  It is 
interesting that the concentration of IGF-I reaches its greatest height at a time when 
at least some mechanisms of neonatal immune tolerance are hypothesized to be 
occurring (Strober, 1984). 
Effect of dexamethasone 
The effect of Dexamethasone on the number of rbIL-2 activated PBMN cells 
is shown in Figure 9.  Dexamethasone inhibited (p < 0.0001) the proliferation of 
the rbIL-2-activated PBMN cells.  Wiegers et al. (1993) have demonstrated that a 
low circulating level of corticoid maintained the immune response while a rather 
high dose of corticoid completely abolished the proliferative response in 
adrenalectomized rats in an in vitro assay using PBMN cells activated with ConA. 
Arya et al. (1984) have reported that the dexamethasone suppresses the proliferation 57 
of human T lymphocytes by inhibiting the synthesis of IL-2 mRNA and also inhibits 
the accumulation of gamma-interferon mRNA in these cells. 58 
Implications 
Growth hormone and PRL have regulatory effects on PBMN cells in vitro. 
Thus, GH and PRL may play a role in the control of proliferation of PBMN cells in 
domestic animals and may have usefulness as immune-response modifiers.  In 
addition, These studies show that sheep PBMN cells have receptors for several 
hormones and suggested that these hormones may be normally involved in 
maintaining the immune system. 
Table III. 1.	  Proliferation effect of ConA and PHA on PBMN cells in sheep. 
Mitogens  0  0.125  0.25  0.5  1.0  2.0 pg/mL 
ConA	  809*  10477  24450  26435  29391  27054 
+127  ±625  ±769  ±626  ±690  ±2335 
PHA	  809  1027  4737  19386  25810  27718 
+127  ±58  +1062  ±265  ±678  ±584 
Numbers represent counts per minute of [3H]- thymidine uptake by cells. 59 
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Figure III. 1. Incubation time vs proliferation of PBMN cells in the 
presence of 2.0 Ag/mL ConA. 60 
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Figure III. 2. Effect of increasing concentration of rbIL-2 on lamb PBMN cells 
in tissue culture. 61 
1 50
 
"C; 
c. 
0 
0 
K.  125
 
4.4 
;is"  100
 
75
 
0  .01 .1  .5  1  2
 
Ovine growth hormone (ug/mL)
 
Figure III. 3. Effect of oGH on proliferation of resting PBMN cells. 62 
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Figure III. 4. Effect of prolactin on proliferation of resting lamb 
PBMN cells. 63 
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Figure III. 5. Effect of growth hormone on rbIL-2-activated PBMN cells 
in vitro with rbIL-2 (500 units/well). 64 
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Figure III. 6. Effect of prolactin on rbIL-2-activated PBMN cells 
in vitro with rbIL-2 (500 units/well) 65 
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Figure III. 7. Effect of IGF-I on resting PBMN cells. 66 
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Figure III. 8. Effect of rbIGF-I on rbIL-2-activated PBMN cells 
in vitro with rbIL-2 (500 units/well). 67 
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Figure III. 9. Effect of dexamethasone on rbIL-2-activated PBMN cells 
in vitro with rbIL-2 (500 units/well). 68 
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Abstract 
This experiment was conducted to determine if growth hormone (GH) 
receptors are present on immune cells of the lamb and if they change with age. 
Simultaneously, we examined age-related changes in plasma growth hormone 
binding protein (GHBP). Blood samples were drawn from crossbred lambs at ages 
of 7, 14, 30, 90, and 150 d after birth.  Peripheral blood mononuclear (PBMN) cells 
were separated from whole blood by Ficoll density gradient centrifugation method 
and plasma was stored at -20° C. 
Specific binding of 1251-hGH to PBMN cells increased from 0.3% at d 7 to 
0.8 ± 0.1% at d 150 (p < 0.03).  Likewise, plasma concentrations of GHBP were 
lowest during the first several weeks of age but increased (p < 0.0001) between 
ages of 30 and 150 d.  Specific binding of GH receptors and GHBP concentrations 
in plasma were positively correlated (r= 0.89; p= 0.049) over age, suggesting 
similar age dependent regulation.  Results indicated that PBMN cells have very low 
GH receptor activity in the lamb. Observation of increased GHBP concentration 
with increased age is in agreement with previous reports showing an age related 
increase in serum GHBP concentration in the pig. 
Key words: Growth hormone receptor, Growth hormone-binding protein, 
Peripheral blood mononuclear cells, lamb. 73 
Introduction 
A new interdisciplinary research area has emerged that involves the study of 
interactions between the immune and endocrine systems (Kao et al., 1992). One 
emerging area of research on the endocrine-immune system interrelationship 
concerns investigation of the presence of hormone binding sites (receptors) on 
immune cells and their roles at the molecular and cellular level.  Binding of GH to 
its receptor is required for regulation of the actions of GH on all tissues (Nicoll et 
al., 1986). 
Binding sites for human GH (hGH) have been previously demonstrated on 
cultured human cell lines such as IM-9 cells (Lesniak et al., 1974 and Asakawa et 
al., 1986) and on human PBMN cells (Kiess and Butenandt, 1985).  Keiss and 
Butenandt (1985) have reported that the specific binding of 125I-hGH by human 
PBMN cells was rapid, reversible, and time and temperature dependent. Scatchard 
analysis (Scatchard, 1949) of 1251 -hGH binding to human PBMN cells revealed a 
receptor with a mean affinity constant of 1.5 x 10-9 M and a maximal binding 
capacity of 7.1x10-11 M. Human GH binds to GH binding sites in ruminant animals 
with a higher affinity than does their own GH (Nicoll et al., 1986b). 
In some studies, GH receptor assays have been carried out on solubilized 
receptors from human lymphocytes (McGuffin et al., 1976). These researchers 
observed more binding to solubilized GH receptors than to intact membrane 
receptors on the circulating immune cells. The development of methods for 74 
solubilization and partial purification of GH receptor from rabbit liver (McIntosh et 
al., 1976) and from lymphocytes (Stewart et al., 1983) has been reported. 
The extracellular domain of the human growth hormone receptor (residues 1 
to 246) occurs naturally in serum in the form of a GHBP, which binds hGH with 
approximately the same affinity as the intact receptor (Fuh et al., 1990). Growth 
hormone binding protein has been identified in human sera (Baumann et al., 1986), 
as well as in rabbit (Ymer and Herington, 1985), mouse (Smith and Talamantes, 
1988), and rat (Amit et al., 1990). It has been shown that the rabbit and human 
serum GHBP is related to and possibly derived from the hepatic GH receptor (Leung 
et al., 1987; Spencer et al., 1988). Growth hormone binding protein in human 
plasma is a single-chain glycoprotein with an estimated molecular weight of 50-60 
kDa. A serum GHBP has also been reported from several species including sheep, 
pig, and chicken (Davis et al., 1992).  In most species, it is thought that the serum 
GHBP is derived mainly from the enzymatic lysis of the extracellular portion of the 
GH receptor (Baumann, 1990). 
Although specific GH receptors have been demonstrated in various tissues of 
a number of species, the presence of GH receptors on domestic animal PBMN cells 
have not been investigated.  This study was conducted to 
1.	  Characterize GH binding sites in PBMN cells of the lamb and age 
related changes in binding activity. 
2.	  Determine concentration of the plasma GHBP from 7 d to 150 d of age. 
3.	  Purify and characterize GH receptors from sheep PBMN cells. 75 
Materials and Methods 
Animals and blood collection 
Fifteen crossbred lambs, ages from 7 d up to 150 d were used. Twenty mL 
blood samples were collected via jugular venipuncture in heparinized vacutaineri 
tubes. Blood samples were placed on ice during collection and transfer to the 
laboratory. 
Chemicals 
Human growth hormone (hGH) was a gift from the National Hormone and 
Pituitary Program2.  Carrier-free sodium 'Iodide was purchased from Amersham3. 
RPMI medium 1640 was obtained from Gibco Laboratories4. 
PBMN cell separation 
The separation of the PBMN cells from whole blood was performed by the 
1 Becton Dikinson, Rutherford, N. J. 07070
 
2 National Hormone and Pituitary Program, NIDDK, USDA, Rockville, MD 20850.
 
Human GH, NIDDK-hGH-I-3.
 
3 Amersham, PRN .1004, Arlington Heights, IL.
 
4 Gibco, Grand Island, New York.
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Ficoll-Histopaque density gradient centrifugation method of Boyum (1968) with 
modification as follows: The heparinized blood was taken from normal sheep in 
sterile vacutainer tubes and centrifuged at 1800 rpm at 8° C for 15 min. The buffy 
coat was diluted 1:3 with RPMI-1640 supplemented with gentamicin5 (50 µg /mL). 
The buffy coat/RPMI mixture was layered onto 8 mL Ficoll Histopaque5 (density 
1.077 µg /mL) in 50-mL sterilized centrifuge tubes. The tubes were then centrifuged 
at 450 x g for 30 min. The PBMN cells were found in the top band of the tube. 
They were harvested, resuspended with RPMI 1640 and washed twice at 1200 rpm 
for 10 min and maintained in the same medium. Before use, the cells were counted 
in a hemocytometer chamber to determine cell number. The viability of the 
separated cells was tested by the trypan blue exclusion method (Moore et al., 1966). 
The preparations contained about 85 to 90% lymphocytes and 4 -6 % monocytes as 
determined by Wright stain.  Contamination with granulocytes was less than 5 %. 
Iodination of growth hormone 
Labeled hGH was prepared by a modification of the method of Greenwood 
and Hunter (1963) which was adapted in our laboratory. A typical iodination 
mixture contained the following reagents which were added in sequence: 25 AL of 
0.5 M sodium phosphate (pH 7.4), 2.5 AL of hGH (1mg/mL), 0.5 mCi sodium 125 
Iodide (carrier-free)  ,  and 30 AL chloramine-T (0.5 mg/mL, Sigma). 
5 Sigma, St. Louis, MO 63178 77 
The reaction mixture was immediately diluted with 1.0 mL of 0.05 M sodium 
phosphate buffer, pH  7.4.  The specific activity of iodinated hGH was determined 
by precipitation of '25I-hGH with 10% trichloroacetic acid. The 125I-hGH was 
purified by passage through a 1.5 x 6 cm anion exchange column (AG 1-X86) and 
eluted with 0.05 M sodium phosphate buffer.  Free iodide was removed with a 1 x 
55 cm Bio Gel P-1006 column (mesh 100-200) using phosphate buffered saline (PBS) 
(0.14 M NaC1, 0.01 M NaPO4, pH  7.4) for elution.  Fractions of 2.0 ml were 
collected in tubes containing 1 mL PBS plus 1% bovine serum albumin' (BSA). 
The '25I-hGH prepared in this way was used immediately for radioreceptor assay 
(RRA) or stored at 4° C for no longer than 2 weeks. 
Radioreceptor assay 
The radioreceptor assays were performed in triplicate at room temperature 
(RT) on the intact freshly separated PBMN cells from whole blood. The PBMN 
cells (5 x 106 cells/tube) were added to 12 x 75 mm borosilicate tubes containing 
100 pL of '25I-hGH  (30,000 cpm) in the absence or presence of an excess (1 pg) of 
unlabeled hGH in a total incubation volume of 0.3 mL in 0.01 M PBS, containing 
10 mM MgC12 and 1% (wt/vol) BSA. Incubation was carried out for 2 h at 32° C 
in a constant temperature water bath with vigorous shaking. 
6 Bio Rad Laboratories, Hercules, CA 94547 
7 Beckman Instruments, Inc. Palo Alto, CA 94303 78 
At the end of the incubation period, 0.5 mL ice-cold PBS-1 %BSA buffer was added 
and the tubes centrifuged at 1000 x g at 4° C for 10 min. Tubes were decanted, air 
dried and the resulting pellet was counted in an automatic gamma counter' (gamma 
5500). Non-specific binding (NSB) was defined as cpm  1251 bound in the presence 
of 1 itg unlabeled hGH; this was determined for every sample.  Specific binding was 
expressed as the difference between total binding and nonspecific binding. A 
preparation of liver microsome was used as a positive control to demonstrate that the 
125I-hGH preparation was indeed able to bind to its receptor. PBMN cells also were 
treated with 4 M MgC12 to remove the endogenously bound growth hormone as 
described by Baginga et al., 1990. 
Solubilized receptors 
The PBMN cells were separated from whole blood and then PBMN cell 
receptors were solubilized immediately in Tris-HC1 buffer, pH 7.5, and Triton X­
100 (1 mg/1 mg protein) as follows:  After stirring the solubilized receptors in a 
shaker for 1 h at room temperature (RT), the mixture was centrifuged at 100,000 x 
g for 1 h. The supernatants were stored in aliquots at -20° C for later binding 
studies.  Protein was determined by a method which has been adapted to measure 
protein in samples containing Triton X-100 (Chandrarajan and Klein, 1975). 
Solubilized receptors (200 itg) were incubated with 30 x 103 cpm of 125I-hGH in the 
absence or presence of 1.0 tcg of unlabeled GH in a final volume of 0.5 ml Tris-HC1 79 
buffer, pH 7.5, containing 1% BSA, 10 mM MgC12 and 10 mM CaC12. 
The samples were incubated at RT overnight on a reciprocal shaker. 
RRA of solubilized GH receptor 
The Triton X-100 extract containing 50 mg protein was incubated 3 hours 
with 125I-GH (30,000 CPM) in 0.5 ml Tris-HC1 pH 7.5, containing 0.1% BSA, 10 
mM MgC12, and 10 mM CaC12. Then, polyethylene glycol (Stewart et al.,  1983) 
was used to precipitate the hormone-receptor complex. The incubation was stopped 
by placing the tubes in ice, adding 0.2 ml of cold 12.5% polyethylene glycol in 25 
mM Tris-HC1 buffer, and then mixing vigorously.  After waiting 10 min to allow 
complete precipitation, the tubes were centrifuged at 2500 x g for 20 min, then the 
tubes were decanted. The tubes were kept inverted on filter paper for 2 h at RT and 
then the radioactivity was counted in a gamma counter. 
GHBP concentration 
Plasma concentrations of GHBP were measured using a competitive enzyme 
linked immunosorbent assay (ELISA) using recombinant bovine GHBP (rbGHBP)8 
and a polyclonal rabbit anti rbGHBP8 (Davis  et al.,  1994).  Briefly, rbGHBP (25 
ng/well in 100 AL of carbonate buffer, 0.1 M, pH 9.6) is added to Costar 
8 Monsanto Company, ST. Louis, MO 63038 80 
high-binding EIA plates and incubated for 48 h at 4° C to coat the well with GHBP. 
On the same day, equal volumes (60 /I L ) of assay buffer (0.1 M PBS, 1 % BSA, 
0.1 Triton X-100, 0.1 % Tween-20), serum or reference standard in assay buffer 
and antiserum (diluted to 1:50,000 in assay buffer) are added on d 1 to wells in a 
low-binding Costar microtiter plate and incubated for 48 h at 4° C.  On d 3, the 
GHBP coated plates were washed 3 times with nanopure water containing 0.1 % 
Tween 20. The GHBP coated plates are then blocked by adding 100 id, of assay 
buffer and incubating at room temperature (RT) for 30 min. The plates were again 
washed 3 times and then 100 it1_, of incubated mixtures from low-binding plates  were 
added to the coated plates and incubated for 24 h at 4° C. On d 4, biotin 
conjugated anti-IgG3, streptavidin conjugated to horseradish peroxidase3 and 
chromogen (3,3,5,5-tetramethylbenzadine were used to for color development. 
Plates were read on a Titertek plate reader at 450 nM. The computer is 
programmed to the reference standard curve and to calculate the relative 
concentration of GHBP in samples by extrapolation from the standard curve. 
Liver microsomal isolation 
A liver from a 1 year old male lamb was collected after slaughter, and liver 
microsomes were prepared as described by Orian et al. (1991). Approximately 1  g 
of liver was diced and then homogenized in 5 volumes of a solution containing 0.3 
M sucrose at 4° C. The homogenate was centrifuged at 1,500 x g for 20 min at 4° 
C. The supernatant was collected and centrifuged at 15,000 x g for a further 20 81 
min at 4° C. The 15,000 x g supernatant was then centrifuged at 100,000 x g for 
90 min at 4° C. The pellet from the 100,000 x g centrifugation was resuspended in 
1 volume of a solution containing 25 mM HEPES, pH 7.5, 10 mM MgC12, and the 
protein concentration was determined by the method of Lowry et al. (1951). 
Membrane preparations thus prepared were stored at -20° C until used for binding 
studies. 
Statistical analysis 
The general linear model (GLM) procedure in SAS, 1985, was used for the 
analysis of variance and comparison of treatment means. The correlation coefficient 
was defined by Pearson's correlation matrix test. 82 
Results and Discussion 
Ontogeny of growth hormone receptor 
Developmental changes in specific binding of 125I-hGH to intact PBMN cells 
are shown in Fig. 1.  Percentage of specific binding per 5 x 106 cells increased (p 
< 0.03) from 0.3% at d 7 to 0.8 ± 0.1% at 150 d.  In the presence of a large 
excess (1 to 2 µg /tube) of unlabeled hGH only a small percentage of the '25I-hGH 
was bound to PBMN cells.  This is referred to as "nonspecific" binding. 
Nonspecific binding tubes were used for each sample to calculate total specific 
binding.  Radioreceptor assay was done at room temperature (RT) and at 2 h 
according to the procedure by Lesniak et al.  (1974).  Cell viability was always more 
than 95 % of the PBMN cells as determined by trypan blue exclusion.  Specific 
binding of '25I-hGH was expressed as percent bound/total radioactivity added per 
tube.  Receptors were considered GH-specific because ovine prolactin (oPRL) failed 
to displace  1251 -hGH from  PBMN cells at doses up to 5 it g.  In our experiment, we 
found that the average binding of 125I-hGH was less than 1.0% of total binding. 
However, cells from some individual lambs and some older ewes exhibited up to 2 
%SB (with 5 x 106 cells per tube).  This is consistent with the observation by Eshet 
et al. (1975) who reported specific binding of '25I-hGH to human circulating 
lymphocytes of 3 and 4% when 10 x 106 lymphocytes were used in their assay. 
In our study, solubilized receptors from cell membranes did not increase the 
specific binding of 125I-hGH to GH binding sites from PBMN cells. The specific 83 
binding stayed the same as that on the freshly isolated PBMN cells and it was under 
1%. Divalent cations and chelating agents such as Triton X-100 have been shown to 
have important effects on some receptor hormone interactions (Gorden and 
Weintraub, 1985). Bonifacino et a/. (1981) have reported that solubilization of the 
membrane receptor increased the specific binding (%) of 125I-hGH to GH receptors 
in rat liver. To investigate whether high concentrations of endogenous sheep GH 
obscured the detection of specific GH receptors on PBMN cells, specific binding of 
1251 -hGH was examined after pretreatment of PBMN cells with a high concentration 
(4 M) of MgC12. Pretreatment with MgC12 to remove endogenously bound hormone 
did not have any effect on the %SB. 
Scatchard plots could not be done because of low binding, so binding affinity 
was not estimated.  In addition, because of the low yield of GH binding sites from 
solubilized PBMN cells, it was not possible to purify and further characterize the 
binding. 
Growth hormone-binding protein 
Plasma concentrations of GHBP were low during the first several weeks of 
age (20 to 27 ng/mL) but increased to 43 ng/mL (p < 0.001) from 30 to 150 d of 
age. These results are agree with those of Mullins and Davis (1992) who have 
reported that GHBP activity increased with age in both sexes of pigs (boar and gilt). 
There is now good evidence that the principal form of GHBP is identical to the 
extracellular domain of the GH receptor (Leung et al., 1987) and that GHBP may be 84 
produced by proteolytic cleavage of the full-length GH receptor (Trivedi and 
Daughaday, 1988; Spencer et al., 1988) or derived from a separate mRNA 
(Baumbach et al., 1989).  Studies of the ontogeny of the GHBP activity in man 
(Daughaday et al., 1987) and the changes in the concentration of the GHBP and 
hepatic GH receptor in pregnant mice ( Smith and Talamantes, 1988) suggest that 
the serum GHBP levels could be a peripheral indicator of GH receptor activity. 
This idea is supported by the finding that patients with Laron-type dwarfism, a 
syndrome caused by the lack of functional hGH receptors, also lack GHBP activity 
in serum (Baumann et al., 1987). 
Relationship between GH receptor and GHBP 
Although GH receptor levels were very low on PBMN cells at all ages 
examined, there was a high positive correlation (r= 0.89, p= 0.049) between GH 
receptor and plasma GHBP levels.  This observation suggest that GH receptor on 
PBMN cells and circulating GHBP are developmentally regulated in a similar 
fashion. 85 
Implications 
In growing lambs, percent specific binding of hGH to PBMN and serum 
concentrations of GHBP were lowest at birth but increased up to 5 months of age. 
These results suggest that concentration of specific GH receptors on PBMN cells 
increases with age and is associated with an increase in GHBP in serum. The 
presence of GH receptors on PBMN cells suggests that GH may be involved in 
modulating the cellular component of the immune system in lambs. 86 
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Figure IV. 1. Ontogeny of the GH receptor on PBMN cells. 87 
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Abstract 
This study was conducted to determine if soluble interleukin-2 (sIL-2) 
receptor activity in serum may be used as an indicator of the status of the immune 
system in ruminants. An assay was developed to measure sIL-2 receptor in serum 
in ruminant animals by using recombinant bovine interleukin-2 (rbIL-2).  Blood 
samples were drawn from cows and serum was collected and stored at -20° C until 
assayed.  Specific binding (SB) of 125I-rbIL-2 to the sIL-2 receptor in bovine serum 
was time dependent (plateau at 6 h) and dose dependent (highest binding at 200 pl of 
serum).  Scatchard analysis of the binding revealed a single order binding with low 
binding affinity (ka= 1.5 + 0.7 x 10-7 M-1) and moderate capacity (Bmax= 5.6 + 
1.2 fmol/mg). 
Serum sIL-2 receptor activity was higher (p < 0.01) in cows infected with 
Bovine Viral Diarrhea (BVD) and/or Infectious Bovine Rhinotracheitis (IBR) than in 
healthy cows [percent SB (%SB) of 5.2 + 0.8 and 3.0 + 0.2, respectively].  In 
addition, serum sIL-2 receptor activity was measured in serum from calves treated 
with selenium (Se), vitamin E, and Se + vitamin E.  Neither Se nor vitamin E 
treatment had an effect (p > 0.05) on serum sIL-2 receptor binding activity in 
calves. The occurrence of Escherichia coli (E. coli) scours, however, was 
associated with an increase (p < 0.01) in serum sIL-2 receptor activity (%SB of 1.8 
+ 0.1 and 2.5 + 0.1 for control (without scours) and scours calves, respectively). 
These results confirm that a soluble form of IL-2 receptor in serum is present in the 95 
bovine species and that the relative amount of this serum receptor is increased in 
diseased calves and cows. Serum IL-2 receptor, therefore, may be of value as an 
indicator of immune response to disease. 
Key words: Soluble interleukin-2 receptor, bovine, vitamin E, selenium, viral 
disease 96 
Introduction 
Interleukin-2 (IL-2), is also known as T cell growth factor, is an 
immunomodulatory factor produced by certain subsets of T-lymphocytes.  It has 
been isolated from a variety of cell cultures and recombinant systems (Smith, 1988). 
Bovine IL-2 is a glycoprotein with an apparent molecular mass of 15.5 kDa and it 
has an amino acid homology of 65% with human IL-2 and 50% with murine IL-2 
(Cerretti et al., 1986).  Interleukin-2 has been shown to promote long term growth 
of T cells, activation and proliferation of natural killer (NK) cells, and B cell growth 
factor secretion (Morgan et al., 1976; Ortaldo et al., 1984; Inaba et al., 1983). 
The receptor for IL-2 plays a crucial role in the regulation of the immune 
response (Smith, 1988). Binding of IL-2 to its receptor on the surface of T 
lymphocytes triggers a series of intracellular signaling events that result in the 
activation and proliferation of resting T cells and ultimately, in the generation of 
helper, suppressor and cytotoxic T cells; all three mediate immune response 
Waldman, 1986). There are three forms of cell-surface IL-2 receptors, each with a 
different affinity for IL-2 (Leonard et al., 1983; Wang and smith, 1987). The low 
affinity receptor (Kd  10 nm) is a 55-kDa polypeptide (p55), the intermediate 
affinity receptor (Kd  1 nm) is a 75-kDa polypeptide (p'75), and the high affinity 
receptor (Kd  10 pm) is a noncovalent complex containing p55 and p75 (Sharon et 
al., 1988; Burton et al., 1990). The p55 protein provides a helper binding function 
with no signalling capacity of its own, while the p75 protein can stimulate cell 
division without the assistance of the p55 chain (Robb and Kutny, 1987).  In the 97 
absence of antigen stimulation, the concentration of cell-surface IL-2 receptor on the 
majority of T cells is not high enough to induce proliferation (Cantrell and Smith, 
1984).  In the presence of antigen, T cells are induced to synthesize and secrete IL-2 
as well as to synthesize cell-surface IL-2 receptor (Meuer et al., 1984).  Different 
affinity forms of IL-2 receptor are synthesized upon stimulation by antigen, leading 
to increased numbers of high affinity receptors on the cell surface.  It appears that 
binding of IL-2 to high affinity receptors is the trigger necessary to promote cell 
cycle progression (Smith and Cantrell, 1985).  Antigen- or lectin-activated T cells 
and certain T- and B-cell lines release a soluble truncated form of p55 IL-2 receptor 
that has an apparent molecular mass of approximately 45 kDa (Rubin et al., 1985). 
Reportedly, there are low levels of sIL-2 receptor in the serum of mice (Osawa et 
al., 1986), rats (Mouzaki et al., 1987) and humans (Rubin et al., 1986). The major 
difference between the soluble and cell-surface forms of low affinity IL-2 receptor is 
that the former comprises only the ligand-binding domain and lacks both 
transmembrane and cytoplasmic domains (Robb and Kutny, 1987). 
Considerable interest has been developed in the use of serum sIL-2 receptor 
as a diagnostic indicator of the immune status in an individual. The level of sIL-2 
receptor in serum is considered as an estimator of T cell activation and has been 
reported in a wide spectrum of human diseases (Rubin and Nelson, 1990). 
Vitamin E enhances antibody biosynthesis and cell mediated immunity in 
vivo (Meydani et al., 1990). Gogu and Blumberg (1993) reported that vitamin E 
increases cellular growth and glycosylation in a murine cytotoxic T-cell line 98 
(CTLL), perhaps via increasing the expression of the IL-2 receptor.  Vitamin E has 
been demonstrated to affect the immune response by enhancing antibody biosynthesis 
and cell mediated immunity in vivo (Gogu and Blumberg, 1993). 
Roy et al. (1993) have shown that dietary supplementation with selenium 
(Se) results in a significant up-regulation of the expression of the IL-2 receptor on 
the surface of ConA-stimulated lymphocytes from mice. Dietary supplementation of 
Se, along with vitamin E, inhibits tumorigenesis and retard tumor growth in animals 
(Stites and Terr, 1991). 
Bovine viral diarrhea (BVD) virus has been associated with diarrhea and 
enteric problems (Radostits and Littlejohns, 1988), abortion (Kahrs, 1968), and 
immunosuppression (Markham and Ramnaraine, 1985).  Signs of acute disease 
include diarrhea, ulceration of the mucosal surface of the mouth, esophagus, 
stomach and intestines, fever, depression, and leukopenia (Kahrs, 1971). When 
pregnant cows are infected with BVD virus up to day 125 of gestation, the calf may 
be aborted or become persistently infected (Radostits and Littlejohns, 1988). 
Occasionally researchers have reported isolation of BVD virus from lungs of cattle 
with respiratory disease.  Reggiardo (1979) stated BVD virus was isolated from 21% 
of lungs with pneumonia in cases of shipping fever. 
The respiratory form of infectious bovine rhinotracheitis (IBR) is 
demonstrated by fever, anorexia, rapid breathing and clear to mucopurulent 
discharge (Rahrs, 1977). An alphaherpesvirus of the family Herpesviridae was 
isolated which is now called bovine herpesvirus type 1 (BHV-1). The virus can 99 
infect goats, deer, and other hoofed ruminant mammals (Yates, 1982).  In field 
conditions, about 25% of BHV-1-infected cows abort within 8 to 100 days. 
The objectives of this study were to: 
1.	  Develop an assay to measure the sIL-2 receptor in bovine serum. 
2.	  Characterize sIL-2 receptor activity in bovine serum. 
3.	  Determine if disease status in the bovine is associated with increased or 
reduced serum IL-2 activity. 
4.	  Determine if either vitamin E or selenium treatment influences 
serum IL-2 receptor activity. 100 
Materials and Methods 
Animals and blood samples 
Experiments to determine the binding capacity and binding affinity of sIL-2 
receptor were carried out using serum from three 3-year old Holstein dairy cows. 
Thirty mL blood was drawn from each animal via jugular venipuncture into plain 
Vacutainerl tubes. Blood samples were centrifuged at 4° C and 1200 x g for 15 
min. The serum was separated and then frozen at -20° C. Sera from diseased and 
healthy adult cows were provided by Dr. Donald E. Mattson2. Sera from calves 
(Hereford) treated with Se and vitamin E were provided by Dr. Harley A. Turner3. 
Iodination 
Iodinated rbIL-2 was prepared by a modification of the chloramine-T method 
described by Khosraviani and Davis (1994). A typical iodination mixture contained 
the following reagents added sequentially into a 2-mL glass vial: 2.68 AL of rbIL-24, 
' Becton-Dickinson, Rutherford, N. J. 07070 
2 College of Veterinary Medicine, Oregon State University, OR 97331 
3 Eastern Oregon Agricultural Experiment Station, Oregon State University, Burns, 
OR 97331 
4 Dr. C. Morrison, Ciba-Geigy, Saint. Aubin Switzerland, CH 1520. 101 
25 AL of 0.5 M sodium phosphate buffer at pH 7.4, 0.5 mCi carrier-free sodium 
125-Iodides, and 30 1AL chloramine-T (0.5 mg/ml of 0.05 M sodium phosphate 
buffer). The mixture was swirled for 50 sec and then 50 ILL of sodium 
metabisulfate (125 itg/50 /AL of 0.05 M sodium phosphate buffer) was added. The 
reaction mixture was immediately diluted with 1.0 mL of 0.05 M sodium phosphate 
buffer at pH 7.4. The contents of the iodinated vial were transferred to a disposable 
anion exchange (AG-108)6 column to separate the iodinated rbIL-2 from free Na­
iodide. The Na-wIodide uptake by rbIL-2 was determined by precipitation of an 
aliquot of 125I-rbIL-2 with 10% trichloroacetic acid. The remaining 125I-rbIL-2 was 
further purified by passage through a 1 x 55 cm P-1006 (mesh 100-200) column with 
0.01 M phosphate buffered saline (PBS) at pH 7.4 for elution. The iodinated rbIL-2 
preparation was used immediately for radioreceptor assay or stored at 4° C for  a 
maximum of 2 weeks. 
Assay conditions 
After the initial studies were performed to establish optimal binding 
conditions, subsequent binding studies were carried out as follows. The assay 
contained two sets of tubes, total binding tubes (TB) and non-specific binding (NSB) 
tubes for each serum sample. 
5 Amersham Life Science, Arlington Heights, Illinois 60005 
6 Bio-Rad Laboratories, Hercules, CA 94547 102 
One hundred AL of serum was added, in duplicate, to 12 x 75 mm borosilicate 
tubes' containing 100 /IL of '25I-rbIL-2 (30,000 cpm) in the absence (for TB) or 
presence (for NSB) of 2.5 eug of unlabeled rbIL-2 in a total 
incubation volume of 0.5 ml PBS buffer containing 0.5 % (wt/vol) bovine serum 
albumin (BSA). Incubation was carried out for 6 h at 32° C in a constant 
temperature water bath with vigorous shaking.  After incubation, 0.5 ml ice-cold 
dextran coated charcoal (2 g activated charcoal, 100-400 mesh and 0.2 g of dextran 
in 0.01 M PBS) was added to each tube. The tubes were vortexed, then centrifuged 
at 2500 x g at 4° C for 15 min. The supernatants, containing bound IL-2, were 
collected and counted in a gamma counter'. 
Effects of time and serum volume 
Binding of labeled rbIL-2 to the soluble form of the IL-2 receptor in serum 
was measured at incubation times varying from 0.5, 1, 2, 4, 6, and 8 h.  In a 
separate assay, serum volumes from 50 to 200 ttL were tested.  Percent specific 
binding (SB) was expressed as the difference between TB and NSB. This method is 
similar to that described by Davis et al. (1992) for measuring serum growth 
hormone-binding protein activity. 
7 Fisher Scientific, Pittsburgh, PA 15219 
' Beckman 5500, Beckman Instruments, Inc. Palo Alto, CA 94303 103 
Binding affinity and capacity 
Scatchard analysis was carried out on data obtained from a competition 
experiment for various concentrations of unlabeled rbIL-2. The assay procedure was 
described in assay condition. Then, binding capacity and affinity were estimated 
using the LIGAND program (Munson and Rodbard, 1980) which was adapted for 
the microcomputer by McPherson (1985). 
Effect of viral diseases on sIL-2 receptor in the cow 
Serum-virus neutralization (SN) tests were performed to measure BVD and 
BHV-1 (IBR) antibodies in Dr. Mattson's Laboratory at the Veterinary School at 
Oregon State University.  Briefly, sera were heat-inactivated at 56° C for 30 min 
and diluted in flat bottom 96 well microtiter plates using 2-fold dilution steps (50 AL 
per well). An equal volume of virus (50 AL) containing 100 tissue culture median 
infectious doses (TCID50) was added to the diluted serum. The plates were 
incubated 1 h at 25° C after which the appropriate cells were added at a 
concentration of 5x105 cells/mL.  Finally, one drop of sterile mineral oil was added 
to each well and the plates incubated at 37° C in a 2.5 % concentration of CO2. The 
plates were examined for cell growth and presence of cytopathic effect after 5 to 7 
d.  Tests were performed in duplicate and the serum end-point titer was defined  as 
the last serum dilution which inhibited the cytopathic effect (CPE) of the virus. 104 
Bovine sera with BVD and IBR antibody titers above 1:256 and up to 1:1024 
were chosen to determine the sIL-2 receptor activity. Bovine sera with negative 
antibody to BVD and IBR were used as a Control. 
Effects of Se, vitamin E, and Se + vitamin E in calves with scours and without
 
scours
 
Forty adult cows for each group were supplemented with Se, vitamin E, and 
Se + vitamin E during pregnancy. After birth, calves was also supplemented with 
Se, vitamin E, and Se+vitamin E. The following table shows the treatment groups. 
Cows  calves 
Treatment 1 = Vitamin E & Se bolus  Vitamin E & Se injections 
Treatment 2 = Se bolus  Se injections 
Treatment 3 = Vitamin E  Vitamin E injections 
Treatment 4 = No vitamin E or Se No vitamin E or Se injections 
The calves of the cows got injections in the following intervals: 
6cc vitamin E and Se (by birth wt.) at birth
 
3cc vitamin E and Se (by birth wt.) at 2 wks
 
3cc vitamin E at 4 wks
 
and the cows got 40cc of vitamin E and slow release Se boluses. Blood samples 
were taken from all calves at birth  ,  7, 14, 21, 28 d.  Sera were isolated and stored 
at -20° C. 105 
All calves were checked for any sign of scours (diarrhea).  Severity of scours was 
scored from 1 to 4 accordance to following list. 
1 = Very mild, slightly discolored, loose stool 
2 = Definitely scours 
3 = Severe, but not near death 
4 = Severe, dehydration, white watery stool 
Sera from the calves with a scours score of 2 to 4 were assayed for sIL-2 receptor. 
Changes in serum sIL-2 receptor activity was also measured in calves without  scours 
from birth to up to 4 wks. 
Statistical analysis 
Soluble IL-2 receptor activity were analyzed with repeated measures analysis 
of variance to test the effects of two factors at weekly interval from birth to 4 weeks 
using the general linear models (GLM) procedure in SAS, 1985. Treatments were 
assigned to the animals according to completely randomized design. The second 
factor consisted of those animals who developed diarrhea and those without diarrhea. 
P value < 0.05 was considered statistically significant. 106 
Results and Discussion 
Effect of time and serum volume 
The binding of 125I-rbIL-2 to serum sIL-2 receptor was time dependent as 
shown in Fig. 1.  At 30° C, a maximum response was observed at 6 h.  Prolonging 
the incubation time up to 8 h resulted in a decline in 125I-rbIL-2 binding to serum 
sIL-2 receptor.  Specific binding of 125I-rbIL-2 increased as the serum volume 
increased to 200 p,L (Fig. 2).  Therefore, in all subsequent experiments, a serum 
volume of 100 iLL was assayed for 6 h incubation time. 
Binding affinity and capacity 
Scatchard analysis (Scatchard, 1949) of binding of 125I-rbIL-2 to serum sIL-2 
receptor suggested a single population of binding sites with a low binding affinity 
(Ka= 1.5 + 0.7 x 10-7 M-1) and moderate capacity (Bmax= 5.6 + 1.2 fmol/mg). 
The displacement curve and Scatchard plot are shown in Fig. 3.  Table 1 shows the 
comparison of the binding characteristics sIL-2 receptor in both ovine and bovine 
serum. 
Effects of Se, vitamin E, and Se + vitamin E in calves 
Treatment of cows and calves with Se, vitamin E, or Se + vitamin E did not 
modulate sIL-2 receptor activity compared with controls.  Control calves showed 107 
slightly lower sIL-2 receptor activity as the calves aged. However, this decline was 
not significant (p > 0.8) (Fig. 4A). Calves treated with Se showed declining 
activity of serum sIL-2 receptor from week-1 to week-4, but this decline was not 
significant (p > 0.10) (Fig. 4B).  Figure 4C and 4D show the sIL-2 receptor 
activity in calves treated with vitamin E, and vitamin E + Se. For these treatments, 
there were no differences in serum sIL-2 receptor activity as the animals grew (p > 
0.9). The control animals were on adequate vitamin E and marginal Se 
supplementation in their diets.  Therefore, it is possible that the over 
supplementation of vitamin E, Se, and vitamin E + Se did not have significant 
effect on sIL-2 receptor activity in compare to those in control animals.  Scours was 
associated with an increase (p < 0.01) in serum sIL-2 receptor activity from 1.8 % 
in healthy calves to 2.5 % in sick calves as shown in Fig. 5.  In a tissue culture 
assay, Gogu and Blumberg (1993) had shown that CTLL cultures in log phase and 
growing in 10% IL-2 medium in the presence of 1-16 pg vitamin E/mL showed a 
dose-dependent 2- to 15-fold stimulation of growth (assessed by 3H- thymidine 
incorporation) relative to control. We did not measure the white blood cell (WBC) 
number to see if vitamin E causes an increase in the WBC population. Meydani et 
al. (1990) have reported that a significant increase in IL-2 formation in response to 
ConA was observed after vitamin E supplementation in healthy elderly humans. 
This suggested that vitamin E probably increased IL-2 receptor and this in turn 
caused an increase in the soluble form of IL-2 receptor in serum. 108 
However, in our experiment, vitamin E did not increase the sIL-2 receptor activity 
in serum in calves. 
Effects of viral diseases in cattle 
Sera from 12 cows with positive high titer antibody against BVD and IBR 
and 17 healthy (negative BVD and IBR antibody titer) cows were studied. Serum 
sIL-2 receptor activity was higher in cows with positive antibody titers against BVD 
and IBR than that in cows with negative antibody titers (Fig. 6).  It should be 
considered that some of the positive animals might be sick with other type of 
infectious diseases. However, the animals were selected as possible to same 
complication. The IL-2 receptor is expressed on and released predominantly by 
activated T cells (Rubin et al., 1985). The level of sIL-2 receptor in serum is 
considered an estimate T cell activation and has been reported to be elevated in a 
variety of diseases in human (Stegeman et al., 1993). For example, Kawasaki 
disease, a virally induced autoimmune-like disease of childhood, results in higher 
sIL-2 receptor level at the acute stage than that at the convalescent stage or in 
controls.  Elevated levels of sIL-2 receptor also have been reported in hematologic 
malignancies and in a wide variety of diseases believed to be associated with 
aberrant immune activation; including collagen vascular diseases, transplant 
rejection, sarcoidosis, and mycobacterial infections (Obara, 1992).  In this study we 
demonstrated that sIL-2 receptor is a marker of disease activity, since it is present in 
higher activity in diseased animals. However, the secretion of sIL-2 receptor could 109 
be variable during the course of the disease due to other concurrent pathological 
events not related to BVD, IBR and scours.  Altogether, these data indicate that sIL­
2 receptor is a useful parameter to monitor the evaluation of BVD, IBR, and scours, 
but it is not a specific diagnostic marker for these diseases. 
In summary these results show that an assay of sIL-2 receptor activity in 
bovine serum has been developed.  In calves, neither Se nor vitamin E treatment had 
an effect on soluble IL-2 receptor binding activity.  Soluble IL-2 receptor activity 
was higher in calves with diarrhea than in those without diarrhea.  Soluble IL-2 
receptor activity was also higher in viral diseased than that in non-diseased cows. 
Serum sIL-2 receptor might serve as a marker for immune response to several kinds 
of infectious diseases. 110 
Implications 
Serum sIL-2 receptor could serves as a marker for an immune response to 
specific disorders.  While the appearance of sIL-2 receptor alone can not be used to 
determine the specific cause of a disease, it provides a useful marker for monitoring 
ongoing immune activity and contributes to the profile of the animal's overall 
assessment of immune and disease status.  Since increased sIL-2 receptor levels have 
been demonstrated in viral infections as well as bacterial infection as described 
above, the appearance of above average titers of the soluble receptor may be 
indicative of the condition of the immune system. Serum levels of sIL-2 receptor 
may also prove to be valuable as a means of monitoring and regulating the success 
of drug therapy. 
Table V. 1. Binding characteristics of '21-rbIL-2 to soluble form of IL-2 receptor 
in ovine and bovine serum. 
Species  KD [Mol]  Bmax [Mol]  Hill Co. 
Sheep  1.30  ± 0.15x10'  8.0 ± 0.85x109  0.90 ± .06 
Cow  1.46  ± 0.67x10-7  5.56 ± 1.20x109  0.92 ± .04 111 
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Figure V. 1. Effect of increasing incubation time on sIL-2
 
receptor activity using '21-rbIL-2.
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Summary 
Ovine PRL and oGH at 100 ng/mL have a stimulatory effect on the resting 
PBMN cell proliferation in vitro.  However, when oGH is combined with IL-2, the 
response occurs at the higher dose of 1 or 2 itg/mL. These data suggest that PRL 
and GH might have regulatory effects on PBMN in sheep probably via specific 
receptors. 
Specific binding of GH to PBMN cells increased from d 7 to d 150, but was 
at a very low level indicating that GH receptors are present, but at low levels. 
Plasma concentrations of GHBP were low during the first several weeks of age but 
increased (p <0.001) from 30 to 150 d of age. There was a positive correlation 
between GH binding to PBMN cells and plasma GHBP (r= 0.89; p= 0.049). 
A binding assay for serum sIL-2 receptor was developed for sheep and 
cattle.  Using this assay, neither selenium nor vitamin E treatment had an effect on 
soluble IL-2 receptor binding activity in calves.  Soluble IL-2 receptor activity was 
higher in calves with diarrhea than those without diarrhea.  Soluble IL-2 receptor 
activity was higher in diseased than in non-diseased cows. Soluble IL-2 receptor 
may prove useful as a marker of immune status in future studies of hormonal 
treatment in vivo. 122 
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APPENDIX 
The following data provides more information regarding the studies described 
in previous chapter. The data presented in Appendix A is additional data for chapter 
IV. The data presented in the Appendix shows the concentration of thymulin in 
lambs from 7 to 150 days of age. 140 
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Thymulin 
Thymulin is produced in the thymus gland. Thymulin, a highly conserved 
nonapeptide, is synthesized within the thymus gland by two discrete populations of 
epithelial cells (Dardenne et al., 1977). Thymic atrophy is seen in experimental 
hypophysectomy or advanced aging.  Previously, investigators have tried to 
determine the deleterious consequences of aging on immune function by implanting 
GH and PRL secretory GH3 pituitary adenoma cells into aging rats (18-24 months 
old). This implantation resulted in partial regeneration of thymic tissue and partial 
restoration of T cell competence for proliferation (Kelly et al., 1986). The 
production of IL-2 was significantly increased in these rats.  Since previous 
observations indicated that GH3 implantation caused a dramatic rise in plasma GH 
and plasma PRL, the authors surmised that these hormones may have been 
responsible for the restoration of T cell responses seen in these animals. However, 
in support of these findings, exogenous GH injection of aging rats resulted in 
augmented spleen cell proliferation and NK cell activity (Davila et al., 1987). Yet 
no morphologic alterations were seen in the thymus of the animals.  Studies 
determining the combined effects of coadministration of exogenous GH and PRL on 
restoration of immune function would be of interest. 143 
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